Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Teva Pharmaceutical Industries Ltd (TEVA)

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,052,962
  • Shares Outstanding, K 1,092,190
  • Annual Sales, $ 16,659 M
  • Annual Income, $ -3,990 M
  • 60-Month Beta 1.46
  • Price/Sales 0.68
  • Price/Cash Flow 2.67
  • Price/Book 1.03
Trade TEVA with:

Options Overview

Details
  • Implied Volatility 35.56%
  • Historical Volatility 40.64%
  • IV Percentile 2%
  • IV Rank 3.45%
  • IV High 117.94% on 03/05/21
  • IV Low 32.61% on 06/04/21
  • Put/Call Vol Ratio 0.59
  • Today's Volume 36,945
  • Volume Avg (30-Day) 38,387
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 1,268,722
  • Open Int (30-Day) 1,175,503

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.56
  • Number of Estimates 4
  • High Estimate 0.59
  • Low Estimate 0.54
  • Prior Year 0.52
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.05 +0.70%
on 06/18/21
11.55 -12.34%
on 06/10/21
-0.55 (-5.15%)
since 05/18/21
3-Month
9.94 +1.81%
on 05/11/21
11.99 -15.60%
on 03/22/21
-1.29 (-11.31%)
since 03/18/21
52-Week
8.44 +19.91%
on 11/05/20
13.30 -23.91%
on 02/09/21
-2.18 (-17.72%)
since 06/18/20

Most Recent Stories

More News
Varicella Zoster Infection Treatment Market 2021 With Covid-19 Impact on Market Share, Size, Revenue, Latest Trends, Business Boosting Strategies, CAGR Status, Growth Opportunities and Forecast 2027

The is segmented on the lines of its drug type, route of administration and regional. Basis of drug type is segmented into Acyclovir, Valacyclovir and Famciclovir. Based on route of administration it...

ABT : 110.33 (-1.16%)
GSK : 39.84 (-1.80%)
NVS : 93.01 (-1.21%)
PFE : 38.81 (-1.70%)
TEVA : 10.12 (-2.69%)
VRX.TO : 30.80 (-3.33%)
Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA(R) (ivermectin) Cream, 1% for Once Daily Treatment of Rosacea

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the U.S. launch of its generic version of once daily SOOLANTRA(R) (ivermectin) Cream,...

TEVA : 10.12 (-2.69%)
Teva Pharmaceutical Industries Ltd. (TEVA) Moves 7.5% Higher: Will This Strength Last?

Teva Pharmaceutical Industries Ltd. (TEVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher...

TEVA : 10.12 (-2.69%)
Multiple Sclerosis Drugs Market to Reach USD 41.99 Billion by 2028; Rising Support from Governments and Launch of Awareness Initiatives to Aid Growth: Fortune Business Insights(TM)

The global multiple sclerosis drugs market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to discover innovative and effective therapies for the treatment...

MRK : 76.61 (-0.80%)
NVS : 93.01 (-1.21%)
PFE : 38.81 (-1.70%)
TEVA : 10.12 (-2.69%)
Glaucoma Therapeutics Market Size, Share, Trends, Analysis and Forecast 2027

The Global is estimated to value over USD 10.1 billion by 2027 end at a CAGR of over 6% during the forecast period 2020 to 2027.

AERI : 16.51 (+1.85%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
NVS : 93.01 (-1.21%)
PFE : 38.81 (-1.70%)
TEVA : 10.12 (-2.69%)
VRX.TO : 30.80 (-3.33%)
Opthalmic Drugs Market Size, Share, Trends, Analysis and Forecast 2027

The Global is poised to value over USD 37 billion by 2027 end at a CAGR of over 4.1% during the forecast period 2020 to 2027.

AGN : 193.02 (+0.02%)
BAYRY : 15.7300 (-1.47%)
NVS : 93.01 (-1.21%)
PFE : 38.81 (-1.70%)
REGN : 537.92 (+0.36%)
SNPHF : 13.8200 (+1.02%)
TEVA : 10.12 (-2.69%)
VRX.TO : 30.80 (-3.33%)
Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions

Building on its intention to improve the lives of Canadians, Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd, is pleased to announce the launch of Life Effects, a peer-to-peer support...

TEVA : 10.12 (-2.69%)
Global Losartan Market Size, Share | Industry Report

Japan, Japan, Fri, 04 Jun 2021 02:43:09 / Comserve Inc. / -- Global Losartan Market With Top Countries Data, Industry Analysis , Size, Share, Revenue, Prominent Players, Developing Technologies, Tendencies...

ABT : 110.33 (-1.16%)
MRK : 76.61 (-0.80%)
NVS : 93.01 (-1.21%)
PFE : 38.81 (-1.70%)
TEVA : 10.12 (-2.69%)
New Clinical and Real-World Data Evaluating Efficacy of AJOVY(R) (fremanezumab-vfrm) Injection Presented at 2021 American Headache Society (AHS) Annual Meeting

Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from clinical and real-world analyses examining the efficacy of AJOVY(R)...

TEVA : 10.12 (-2.69%)
Teva to Present Latest Data on AJOVY(R) (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, Showcasing Teva's Longstanding Heritage in the Management of Migraine

Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that 11 presentations examining clinical and real-world data for AJOVY(R)...

TEVA : 10.12 (-2.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

3rd Resistance Point 10.63
2nd Resistance Point 10.50
1st Resistance Point 10.31
Last Price 10.12
1st Support Level 9.99
2nd Support Level 9.86
3rd Support Level 9.67

See More

52-Week High 13.30
Fibonacci 61.8% 11.44
Fibonacci 50% 10.87
Fibonacci 38.2% 10.30
Last Price 10.12
52-Week Low 8.44

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar